Mega-Merger Could Usher In New Era Of Consolidation
Executive Summary
Given the looming patent cliff facing drug manufacturers and the lack of new products coming out of R&D to replace lost sales, it's hardly surprising that murmurings of industry consolidation are swirling
You may also be interested in...
Sanofi CEO Debuts With Sobering News
Sanofi ‘s 2008 financials were solid, but future growth is a challenge.
Bristol Readies Saxagliptin Launch In Anticipation Of FDA Approval
Bristol-Myers Squibb expects its next launch, diabetes drug Onglyza, along with its expanding string of "pearls" - partnership deals - will place the firm in a superior position to offset generic losses in 2012
Bristol Readies Saxagliptin Launch In Anticipation Of FDA Approval
Bristol-Myers Squibb expects its next launch, diabetes drug Onglyza, along with its expanding string of "pearls" - partnership deals - will place the firm in a superior position to offset generic losses in 2012